TY - JOUR
T1 - STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma
AU - Coppo, P.
AU - Gouilleux-Gruart, V.
AU - Huang, Y.
AU - Bouhlal, H.
AU - Bouamar, H.
AU - Bouchet, S.
AU - Perrot, C.
AU - Vieillard, V.
AU - Dartigues, P.
AU - Gaulard, P.
AU - Agbalika, F.
AU - Douay, L.
AU - Lassoued, K.
AU - Gorin, N. C.
PY - 2009/9
Y1 - 2009/9
N2 - Nasal-type natural killer (NK) cell lymphoma is an infrequent aggressive malignant disease with very poor prognosis. We aimed to explore the possible role of the transcription factor STAT3 in the pathophysiology of this malignancy, as it was involved in oncogenesis and chemoresistance. For this, we established and characterized a continuous interleukin 2-dependent NK cell line (MEC04) from a patient with a fatal nasal-type NK-cell lymphoma. Cells harbored poor cytotoxic activity against K562 cells, and spontaneously secreted interferon-γ, interleukin-10 and vascular-endothelium growth factor in vitro. STAT3 was phosphorylated in Y705 dimerization residue in MEC04 cells and restricted to the nucleus. Y705 STAT3 phosphorylation involved JAK2, as exposure of cells to AG490 inhibitor inhibited Y705 STAT3 phosphorylation. By using recombinant transducible TAT-STAT3-β (β isoform), TATSTAT3Y705F (a STAT3 protein mutated on Y705 residue, which prevents STAT3 dimerization) and peptides inhibiting specifi-cally STAT3 dimerization, we inhibited STAT3 phosphorylation and cell growth, with cell death induction. Finally, STAT3 was phosphorylated in Y705 residue in the nuclei of lymphoma cells in eight/nine patients with nasal-type NK/T-cell lymphoma and in YT, another NK cell line. Our results suggest that STAT3 protein has a major role in the oncogenic process of nasal-type NK-cell lymphomas, and may represent a promising therapeutical target.
AB - Nasal-type natural killer (NK) cell lymphoma is an infrequent aggressive malignant disease with very poor prognosis. We aimed to explore the possible role of the transcription factor STAT3 in the pathophysiology of this malignancy, as it was involved in oncogenesis and chemoresistance. For this, we established and characterized a continuous interleukin 2-dependent NK cell line (MEC04) from a patient with a fatal nasal-type NK-cell lymphoma. Cells harbored poor cytotoxic activity against K562 cells, and spontaneously secreted interferon-γ, interleukin-10 and vascular-endothelium growth factor in vitro. STAT3 was phosphorylated in Y705 dimerization residue in MEC04 cells and restricted to the nucleus. Y705 STAT3 phosphorylation involved JAK2, as exposure of cells to AG490 inhibitor inhibited Y705 STAT3 phosphorylation. By using recombinant transducible TAT-STAT3-β (β isoform), TATSTAT3Y705F (a STAT3 protein mutated on Y705 residue, which prevents STAT3 dimerization) and peptides inhibiting specifi-cally STAT3 dimerization, we inhibited STAT3 phosphorylation and cell growth, with cell death induction. Finally, STAT3 was phosphorylated in Y705 residue in the nuclei of lymphoma cells in eight/nine patients with nasal-type NK/T-cell lymphoma and in YT, another NK cell line. Our results suggest that STAT3 protein has a major role in the oncogenic process of nasal-type NK-cell lymphomas, and may represent a promising therapeutical target.
KW - Epstein-Barr virus
KW - Hemophagocytic syndrome
KW - Natural killer
KW - STAT3
UR - http://www.scopus.com/inward/record.url?scp=70349322986&partnerID=8YFLogxK
U2 - 10.1038/leu.2009.91
DO - 10.1038/leu.2009.91
M3 - 文章
C2 - 19421230
AN - SCOPUS:70349322986
SN - 0887-6924
VL - 23
SP - 1667
EP - 1678
JO - Leukemia
JF - Leukemia
IS - 9
ER -
